# Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

> **NCT06848426** · NA · NOT_YET_RECRUITING · sponsor: **Jiangxi Provincial People's Hopital** · enrollment: 100 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer Recurrent
- Non-small Cell Lung Cancer Stage IIIB
- Non-small Cell Lung Cancer Stage IV
- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Xingbaiji Formula

## Key facts

- **NCT ID:** NCT06848426
- **Lead sponsor:** Jiangxi Provincial People's Hopital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848426, "Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06848426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*